<DOC>
	<DOC>NCT00980200</DOC>
	<brief_summary>The study is a multi-center, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of selected doses and dose intervals of the novel long acting beta agonist (LABA), GW642444 in asthmatic subjects ≥18 years of age who are currently receiving inhaled corticosteroid treatment.</brief_summary>
	<brief_title>Efficacy and Safety Study in Subjects With Asthma</brief_title>
	<detailed_description>The study will be a five-period cross-over study with each 7 day treatment period separated by a 7 day wash-out period. The study will enroll asthmatic subjects ≥18 years of age who are currently receiving inhaled corticosteroid treatment with an FEV1 of between 40-85% of predicted normal and with airway reversibility as demonstrated by an increase in FEV1 of ≥12% and ≥200ml . Efficacy assessments include 24-hour serial lung function testing. Safety assessments include incidence of adverse events and measurement of vital signs.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Outpatient ≥18 years of age at Visit 1 Male or Eligible Female Diagnosis of asthma at least 12 weeks prior to Visit 1 Disease reversibility Current antiasthma therapy Appropriately signed and dated informed consent has been obtained Able to comply with all the study requirements History of LifeThreatening Asthma No use of systemic corticosteroids for any indication within 8 weeks prior to Visit No concurrent diseases/abnormalities that would put the safety of the subject at risk through study participation Drug Allergy to β2 agonist or sympathomimetic drugs, or known or suspected sensitivity to lactose or magnesium stearate History of severe milk protein allergy Noncompliance with study medication and other studyrelated requirements No use of inhaled tobacco products within the past three months or historical use of 10 pack years or more Administration of prohibited medications and nondrug therapies and corresponding timeframes as outlined in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>GW642444</keyword>
	<keyword>once daily dosing</keyword>
	<keyword>asthma</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>FEV1</keyword>
</DOC>